Intercept rises 14% to $343.49 as trial link circulated Shares of Intercept Pharmaceuticals (ICPT) are significantly higher in late morning trading, with the move up potentially related to the circulation of a link to data on a clinical trial being run by Intercept for its study to test Obeticholic Acid's effectiveness when used in patients with moderately severe alcoholic hepatitis. The trial was initially posted to the government's ClinicalTrials.gov website in January, though it is unclear if new data has been made available via the site or otherwise. Reference Link
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.